Myeloma Clinical Trial
— IFM2005-02Official title:
Relevance of Maintenance Therapy Using Lenalidomide (Revimid®) After Autologous Stem Cell Transplantation Patients Under the Age Of 65. (Open, Randomised, Multi-centric Trial Versus Placebo).
| Verified date | April 2019 |
| Source | University Hospital, Toulouse |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
Maintenance treatment of myeloma.
| Status | Completed |
| Enrollment | 614 |
| Est. completion date | September 2018 |
| Est. primary completion date | September 2017 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | All |
| Age group | 18 Years to 65 Years |
| Eligibility |
Inclusion Criteria: - No signs of progression after transplant - Effective contraception if necessary (oral contraception for females and barrier methods of contraception for sexually active males) - No active severe infection - Satisfactory restoration of the haematological parameters defined by: PN >1,000/mm3 and Platelets > 75,000/mm3 - Bilirubin < 35 umol/l and GOT/GPT/PAL<3N - Creatinine < 160 umol/l. |
| Country | Name | City | State |
|---|---|---|---|
| Belgium | Algemeen Centrumziekenhuis Antwerpen | Antwerpen | |
| Belgium | UZA Antwerpen | Antwerpen | |
| Belgium | ZNA Middelheim | Antwerpen | |
| Belgium | Hôpital Saint Joseph | Arlon | |
| Belgium | Institut Jules Bordet | Bruxelles | |
| Belgium | UCL St Luc | Bruxelles | |
| Belgium | Hôpital Saint Joseph | Gilly | |
| Belgium | Hôpital Jolimont | Haine Saint Paul | |
| Belgium | Heilig Hart Ziekenhuis | Roeselare | |
| Belgium | UCL Mont-Godinne | Yvoir | |
| France | CH | Aix-en-Provence | |
| France | CHRU | Amiens | |
| France | CHRU Hôpital du Bocage | Angers | |
| France | Centre hospitalier Argenteuil Victor Dupouy | Argenteuil | |
| France | Centre hospitalier Duffaut | Avignon | |
| France | Centre hospitalier de la côte basque | Bayonne | |
| France | Hôpital Jean Minjoz | Besançon | |
| France | CH | Blois | |
| France | Hôpital Avicenne | Bobigny | |
| France | CHRU Hôpital haut Lévêque | Bordeaux | |
| France | Polyclinique Bordeaux Nord Aquitaine | Bordeaux | |
| France | Hôpial Morvan | Brest | |
| France | Centre Baclesse | Caen | |
| France | Polyclinique du Parc | Caen | |
| France | CH William Morey | Châlon-sur-Saône | |
| France | CH | Chartres | |
| France | Hôpital Antoine Béclère | Clamart | |
| France | Hôpital d'instruction des Armées Percy | Clamart | |
| France | CHRU Hôtel Dieu | Clermont Ferrand | |
| France | CH Louis Pasteur | Colmar | |
| France | CHU Henri Mondor | Créteil | |
| France | CHRU Dijon | Dijon | |
| France | Centre hospitalier général | Dunkerque | |
| France | CHRU Hôpital Michallon | Grenoble | |
| France | Centre hospitalier départemental | La Roche sur Yon | |
| France | CH | Le Mans | |
| France | CHRU Hôpital Claude Huriez | Lille | |
| France | Centre hospitalier Bodelio | Lorient | |
| France | Centre Léon Bérard | Lyon | |
| France | CHU Hôpital Edouard Herriot | Lyon | |
| France | Hôpital Nord | Marseille | |
| France | Institut Paoli Calmette | Marseille | |
| France | Hôpital Notre Dame de Bon Secours | Metz | |
| France | CHRU Hôpitaux de Brabois | Nancy | |
| France | CHRU Hôtel Dieu | Nantes | |
| France | Centre Antoine Lacassagne | Nice | |
| France | Hôpital Archet | Nice | |
| France | Hôpital de l'Archet | Nice | |
| France | CHU Hôpital St Antoine | Paris | |
| France | Hôpital Cochin | Paris | |
| France | Hôtel Dieu | Paris | |
| France | Centre hospitalier Lyon Sud | Pierre Bénite | |
| France | CHRU Hôpital Jean Bernard | Poitiers | |
| France | Centre hospitalier de la région d'Annecy | Pringy | |
| France | Hôpital Debré | Reims | |
| France | CHRU Hôpital de Pontchaillou | Rennes | |
| France | CHRU Hôpital Sud | Rennes | |
| France | Centre hospitalier de Roanne | Roanne | |
| France | Centre Henri Becquerel | Rouen | |
| France | Centre hospitalier de la Réunion | Saint-Denis | |
| France | Centre hospitalier Yves Le Foll | St Brieuc | |
| France | Institut de Cancérologie de la Loire | St-Priest-en-Jarez | |
| France | CHRU Hôpital de Hautepierre | Strasbourg | |
| France | CHU Toulouse Purpan | Toulouse | |
| France | CHU Toulouse Rangueil | Toulouse | |
| France | CHRU Hôpital Bretonneau | Tours | |
| France | Centre hospitalier | Troyes | |
| France | CH Chubert | Vannes | |
| Switzerland | Center of Oncology/Hematology and transfusion Medicine, Kantonsspital | Aarau | |
| Switzerland | Universitäts Spital | Basel | |
| Switzerland | Istituto Oncologico Sviss. Italiana IOSI Ospedale Regionale Bellinzona e Valli | Bellinzona | |
| Switzerland | Inselspital | Bern | |
| Switzerland | Hôpital cantonal | Genêve | |
| Switzerland | CHUV | Lausanne | |
| Switzerland | Onkologie/Hämatologie Kantonsspital st Gallen | St Gallen | |
| Switzerland | Spital Thun-Simmental Onkologiezentrum | Thun | |
| Switzerland | Institute of Oncology and Hematology Stadtspital Triemli | Zürich |
| Lead Sponsor | Collaborator |
|---|---|
| University Hospital, Toulouse | Celgene, Intergroupe Francophone du Myelome |
Belgium, France, Switzerland,
Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group. J Clin Oncol. 1998 Dec;16(12):3832-42. — View Citation
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Determine the efficacy of Revlimid® at prolonging the duration of the post-transplant response. | 2 years | ||
| Secondary | Assess the impact of Revlimid® on the post-transplant complete response rate | 2 years | ||
| Secondary | Compare survival without events and overall survival of patients in the lenalidomide arm with the control | 2 years | ||
| Secondary | Evaluate the long-term tolerance of Revlimid® in post-transplant maintenance therapy. | 3 years |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03832127 -
Evaluation of PET 18F-Fludarabine for the Initial Assessment and End-treatment of Symptomatic Multiple Myeloma Patients
|
Phase 1 | |
| Completed |
NCT01413178 -
A Randomized Trial to Compare Busulfan + Melphalan 140 mg/m2 With Melphalan 200 mg/m2 as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma
|
Phase 3 | |
| Recruiting |
NCT03641456 -
VRD as Induction Followed by VR Maintenance in Patients With Newly Diagnosed High Risk Multiple Myeloma
|
Phase 2 | |
| Completed |
NCT03135925 -
Feasibility of Pre Transplant Exercise (Pre-habilitation) for Multiple Myeloma Patients Awaiting Autologous Stem Cell Transplantation
|
N/A | |
| Terminated |
NCT02907073 -
Positron Emission Tomography (PET) Imaging Studies With NIS Reporter
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT02114502 -
Carfilzomib/SAHA Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant in Myeloma
|
Phase 2 | |
| Completed |
NCT00794261 -
Stem Cell Mobilization With Pegfilgrastim in Lymphoma and Myeloma
|
Phase 2 | |
| Completed |
NCT00800839 -
Busulfan and Fludarabine Followed by Post-transplant Cyclophosphamide
|
Phase 2 | |
| Completed |
NCT01700608 -
Prospective Observational Study on Plerixafor After Chemotherapy
|
N/A | |
| Completed |
NCT00606437 -
Total Body Irradiation With Fludarabine Followed by Combined Umbilical Cord Blood (UCB) Transplants
|
Phase 1 | |
| Recruiting |
NCT05528887 -
Study of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Hematological Malignancies
|
Phase 1 | |
| Recruiting |
NCT05625971 -
Non-invasive MRD Assessment in Multiple Myeloma
|
||
| Active, not recruiting |
NCT02931942 -
Changing Over Time of Ascorbic Acid After Chemotherapy
|
||
| Active, not recruiting |
NCT05889221 -
Multicenter Phase 2 Study of Subcutaneous Isatuximab Plus Bortezomib, Lenalidomide and Dexamethasone in the Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma
|
N/A | |
| Recruiting |
NCT03836690 -
Transfer of Effector Memory T Cells (Tem) Following Allogeneic Stem Cell Transplantation
|
Phase 1 | |
| Active, not recruiting |
NCT02542657 -
Ixazomib With Pomalidomide, Clarithromycin and Dexamethasone in Treating Patients With Multiple Myeloma
|
Phase 1/Phase 2 | |
| Completed |
NCT01191060 -
Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years
|
Phase 3 | |
| Completed |
NCT01279694 -
Trial of Carfilzomib Plus Melphalan and Prednisone in Elderly Untreated Patients With Multiple Myeloma (CARMYSAP)
|
Phase 1/Phase 2 | |
| Terminated |
NCT00983346 -
Effect of Low Dose Bortezomib on Bone Formation in Smoldering Myeloma Patients
|
Phase 2 | |
| Completed |
NCT00476294 -
Long-Term Follow Up Study for AMD3100 Patients
|
N/A |